View on Pubmed.gov 32647796 | View on doi.org 10.1097/HS9.000...
Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia.
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY, United Kingdom.
- Department of Hematology, University of Cambridge, CB2 0XY, United Kingdom.
- Department of Hematology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, United Kingdom.
- York Biomedical Research Institute, Department of Biology, University of York, York, YO10 5NG, United Kingdom.
- Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY, United Kingdom. Department of Hematology, University of Cambridge, CB2 0XY, United Kingdom.
- Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland.
- Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
- Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
- Department of Hematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
Abstract
Myeloproliferative neoplasms (MPNs) are characterized by deregulation of mature blood cell production and increased risk of myelofibrosis (MF) and leukemic transformation. Numerous driver mutations have been identified but substantial disease heterogeneity remains unexplained, implying the involvement of additional as yet unidentified factors. The inflammatory microenvironment has recently attracted attention as a crucial factor in MPN biology, in particular whether inflammatory cytokines and chemokines contribute to disease establishment or progression. Here we present a large-scale study of serum cytokine profiles in more than 400 MPN patients and identify an essential thrombocythemia (ET)-specific inflammatory cytokine signature consisting of Eotaxin, GRO-α, and EGF. Levels of 2 of these markers (GRO-α and EGF) in ET patients were associated with disease transformation in initial sample collection (GRO-α) or longitudinal sampling (EGF). In ET patients with extensive genomic profiling data (n = 183) cytokine levels added significant prognostic value for predicting transformation from ET to MF. Furthermore, CD56 +CD14 + pro-inflammatory monocytes were identified as a novel source of increased GRO-α levels. These data implicate the immune cell microenvironment as a significant player in ET disease evolution and illustrate the utility of cytokines as potential biomarkers for reaching beyond genomic classification for disease stratification and monitoring.
References
Blood Cancer J. 2018 Feb 9;8(2):15
J Clin Oncol. 2011 Apr 1;29(10):1356-63
Int J Mol Sci. 2016 Jul 05;17(7):
Blood. 2012 Aug 16;120(7):1409-11
Cited by 50 citations (total)
Journal Article Review
Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR-ABL-Negative Myeloproliferative Neoplasm.
Electronic publication date October 30, 2020
Alessandro Allegra [...] Sebastiano Gangemi et al.
Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) have recently been revealed to be related to chronic inflammation, oxidative stress, and the accumulation...
Journal Article Review
The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.
Electronic publication date November 17, 2021
Lucia Catani [...] Francesca Palandri et al.
Myeloproliferative Neoplasms (MPN) are acquired clonal disorders of the hematopoietic stem cells and include Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis....
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Copyright
Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.